Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2015-01-05 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于召开2015年第一次临时股东大会的会议的补充通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of a 2015 first extraordinary shareholders' meeting (临时股东大会) for Kunming Pharmaceutical Group Co., Ltd. It includes information on meeting time, agenda items, voting procedures (both in-person and online), and proxy authorization forms. The content focuses on the announcement and procedural details for the shareholders' meeting, including proposals to be voted on, such as non-public stock issuance, amendments to company articles, and related party transactions. There are no financial statements, earnings data, or management discussion and analysis. The document is not a report of results or minutes but a formal meeting notice and instructions for shareholders to participate and vote. This fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2015-01-05 Chinese
关于2015年第一次临时股东大会增加临时提案的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement regarding the addition of a temporary proposal to the agenda of the company's 2015 first extraordinary general meeting (临时股东大会). It details the proposals to be discussed and voted on at the meeting, including non-public stock issuance and related transactions. The document is a formal notice about the meeting agenda changes and does not contain financial statements or detailed financial analysis. It is not a full report but an announcement related to shareholder meeting matters, specifically about proposals and voting items. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it pertains to shareholder meeting proposals and voting matters.
2015-01-05 Chinese
华方医药科技有限公司现金认购集团股份有限公司非公开发行股票收购报告书摘要
M&A Activity Classification · 95% confidence The document is titled as a "非公开发行股票收购报告书摘要" which translates to "Non-public Stock Issuance Acquisition Report Summary." It involves detailed information about a stock acquisition by 华方医药科技有限公司 of shares in 昆明制药集团股份有限公司. The document references relevant Chinese laws and regulations such as the Company Law, Securities Law, and the Measures for the Administration of Takeovers of Listed Companies. It includes detailed sections on the acquirer, control relationships, business scope, financial conditions, and legal compliance. The document is a comprehensive acquisition report related to a non-public stock issuance and acquisition, which fits the category of a takeover or merger-related filing. Given the detailed nature and the focus on acquisition, the document best fits the category of M&A Activity (Code: TAR). The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or summary notice.
2014-12-31 Chinese
关于2015年第一次临时股东大会延期召开的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the postponement of the 2015 first extraordinary general meeting (临时股东大会) of Kunming Pharmaceutical Group Co., Ltd. It details the new date and time for the meeting and explains the reason for the delay. There is no financial data, no report attached or published, and no mention of voting results or other report types. The document is a formal announcement about the scheduling of a shareholder meeting, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like AGM Information or Declaration of Voting Results. The document length is short (1252 characters), and it is not a report itself but an announcement about a meeting date change.
2014-12-31 Chinese
募集资金使用情况鉴证报告
Regulatory Filings Classification · 90% confidence The document contains only references to omitted pictures and has a very short length (935 characters). There is no textual content indicating any report, announcement, or detailed information. Given the lack of substantive text and the presence of only images (which are omitted), it is not possible to classify this as a full report or detailed filing. The document is likely a placeholder or an announcement with images only, which fits best under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2014-12-29 Chinese
非公开发行股票预案
Capital/Financing Update Classification · 95% confidence The document is titled as a "非公开发行股票预案" which translates to "Non-public Issuance of Shares Proposal" by Kunming Pharmaceutical Group Co., Ltd. It details the plan for a non-public issuance of A shares, including the background, purpose, issuance details, pricing, use of proceeds, related party transactions, and approvals required. The document includes extensive financial data, company background, and regulatory compliance information related to the issuance of new shares. This is a detailed capital raising plan and update on financing activities rather than a general annual report, earnings release, or other types of filings. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is the actual proposal, not just an announcement of a report, and it is not a regulatory filing or proxy statement. Confidence is high given the clear focus on a non-public share issuance plan and related financing details.
2014-12-29 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.